Skip to Content

SATURDAY, 24 MARCH 2018, 19:46


EMA panel recommends against Portola’s clot prevention drug

Yesterday at 15:05 PM, via Reuters

(Reuters) – A panel of European Medicines Agency on Friday recommended against granting marketing approval to Portola Pharmaceuticals Inc’s oral blood thinner, saying the benefits of the drug did not outweigh risks.

Sad in the spring? Allergy-mood link is real

Yesterday at 11:53 AM, via CNN

You know spring has sprung when hundreds of people daily turn to Twitter to vent about their itchy eyes, dripping nose and uncontrollable sneezing and coughing.

How to succeed at intermittent fasting

Yesterday at 11:37 AM, via CNN

“Intermittent fasting,” a dieting approach that involves cycling between periods of eating and abstaining from food, has been trending in diet circles. This is in part because reports claim that celebrities such as Beyonce, Hugh Jackman, Ben Affleck and Nicole Kidman are doing it but also because increasingly more research reveals that the eating pattern may promote weight loss and improve...

Femtech: Healthcare’s Next Big Disruptor

Yesterday at 09:00 AM, via eHealth News

Research and consulting company, Frost & Sullivan has released new data predicting that female technology (Femtech) will have a market potential of $50 billion by 2025.

According to its report, Femtech is on the cusp of explosive growth, spurred by almost $1 billion in funding over the last three years.

Femtech refers to software, diagnostics, products and services that harness technology to...

Drug-resistant TB Escalating in SA

Yesterday at 09:00 AM, via eHealth News

While the incidence of drug-susceptible tuberculosis (DS-TB), which is treated with the antibiotics rifampicin and isoniazid, has marginally declined in the past decade, there has been a marked increase in drug-resistant TB (DR-TB).

The gains worldwide in controlling TB are threatened by the increase in DR-TB, notably multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB. The...

Novartis touts U.S. filing plans for MS drug as patent losses loom

Yesterday at 01:33 AM, via Reuters

ZURICH (Reuters) – Novartis plans to file its BAF312 multiple sclerosis drug for U.S. approval within weeks, the Swiss drugmaker said on Friday, as it seeks to refresh its portfolio of neurological medicines that is about to be hit by patent losses.

  1. Pages:
  2. 1
  3. 2
  4. 3
  5. 4
  6. 5
  7. ...
  8. 16